Compare GNE & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNE | RZLT |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 321.6M |
| IPO Year | 2011 | 2011 |
| Metric | GNE | RZLT |
|---|---|---|
| Price | $14.03 | $3.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $16.00 | $9.67 |
| AVG Volume (30 Days) | 57.8K | ★ 1.1M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 95.65 | 26.32 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $425,202,000.00 | N/A |
| Revenue This Year | $17.49 | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $128.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.69 | $1.07 |
| 52 Week High | $28.47 | $11.46 |
| Indicator | GNE | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 52.06 |
| Support Level | $13.93 | $2.91 |
| Resistance Level | $14.85 | $3.60 |
| Average True Range (ATR) | 0.48 | 0.20 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 57.00 | 65.12 |
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.